Antegenes provides at-home genetic testing that utilizes a Polygenic Risk Score (PRS) to assess individual cancer risk based on genetic variants, age, gender, and background. This approach enables the creation of personalized cancer prevention plans, significantly improving early detection and potentially reducing cancer mortality rates by 30-40%.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Individual cancer risk varies significantly, even without a family history, and early detection is crucial for improving outcomes. Traditional cancer screening methods often detect tumors at advanced stages, leading to poorer prognoses and higher mortality rates.
Solution
Antegenes offers at-home genetic tests that utilize a Polygenic Risk Score (PRS) to provide personalized cancer risk assessments. By analyzing an individual's genetic variants, age, gender, and background, Antegenes calculates the risk of developing specific cancers and delivers tailored prevention plans. These plans enable proactive steps towards early detection and can potentially reduce cancer mortality rates. The tests have been validated using data from the UK Biobank and Estonian Biobank.
Target Audience
The primary audience includes individuals aged 30-75 (women) and 40-70 (men) seeking proactive cancer prevention strategies, as well as healthcare institutions looking to implement precision prevention programs.
Features
- At-home saliva-based genetic testing for personalized cancer risk assessment
- Polygenic Risk Score (PRS) analysis combining thousands of genetic variants with personal background
- Individualized prevention plans with clinical recommendations for early detection
- Risk assessment for breast, prostate, colorectal, and melanoma cancers
- User-friendly interface and comprehensive reports for easy interpretation of genetic information
- Tests validated using data from the UK Biobank and Estonian Biobank
- ISO 13485 certified management system